Befotertinib after surgery for early-stage lung cancer with EGFR mutation
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer (mainly a type called adenocarcinoma) that has a common EGFR mutation (exon 19 deletion or L858R).
- Your cancer was stage IB, II, IIIA, or IIIB (T3N2M0) and was completely removed by surgery, with no cancer cells left at the edges.
- You are at least 18 years old, and your surgery was 4 to 10 weeks ago with full wound healing.
- You have not had brain metastases and you do not have any other active cancer or serious heart or lung conditions.
- You are willing to use effective birth control during the study and for 3 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This trial tests different targeted therapies after surgery to lower the risk of early-stage lung cancer returning. It's designed for patients with high-risk features, and the treatment depends on the genetic changes in the tumor.
This trial studies a pill called icotinib, given after lung cancer surgery, to see if it helps prevent the cancer from returning in people with early-stage, EGFR-mutant non-small cell lung cancer. It is a real-world study, meaning it looks at how the treatment works in routine practice.
This Phase 2 trial studies whether an EGFR-targeted pill, given after surgery, can reduce the chance of lung cancer coming back. It specifically looks at people whose tumors have certain EGFR changes and where “minimal residual disease” (tiny leftover cancer) is being used to guide treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.